CKD-504
/ Chong Kun Dang
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
April 01, 2022
Therapeutic Potential of CKD-504, a Novel Selective Histone Deacetylase 6 Inhibitor, in a Zebrafish Model of Neuromuscular Junction Disorders.
(PubMed, Mol Cells)
- "In the present study, we demonstrated that HDAC6 inhibition was sufficient to enhance movement by restoring NMJ impairments observed in a zebrafish disease model. We found that CKD-504, a novel HDAC6 inhibitor, was effective in repairing NMJ defects, suggesting that treatment of neurodegenerative diseases via NMJ targeting is possible."
Epigenetic controller • Journal • CNS Disorders • Genetic Disorders • Pain
December 28, 2021
HDAC6 Inhibition Corrects Electrophysiological and Axonal Transport Deficits in a Human Stem Cell-Based Model of Charcot-Marie-Tooth Disease (Type 2D).
(PubMed, Adv Biol (Weinh))
- "Treatment with histone deacetylase 6 inhibitors, tubastatin A and CKD504, improves mitochondrial movement and α-tubulin acetylation in these cells. Furthermore, CKD504 treatment enhances population-level electrophysiological activity, highlighting its potential as an effective treatment for CMT2D."
Journal • CNS Disorders • Genetic Disorders • Pain
January 20, 2021
A novel histone deacetylase 6 inhibitor improves myelination of Schwann cells in a model of Charcot-Marie-Tooth disease type 1A.
(PubMed, Br J Pharmacol)
- "A novel HDAC6 inhibitor, CKD-504, has potent therapeutic efficacy for CMT1A."
Journal • CNS Disorders • Genetic Disorders • Pain • HSP90AA1
February 07, 2020
CKD-504 in SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects
(clinicaltrials.gov)
- P1; N=88; Recruiting; Sponsor: Chong Kun Dang Pharmaceutical; Trial completion date: Feb 2020 ➔ Dec 2020; Trial primary completion date: Nov 2019 ➔ Dec 2020
Clinical • Trial completion date • Trial primary completion date
November 27, 2019
Acetylation changes tau interactome to degrade tau in Alzheimer's disease animal and organoid models.
(PubMed, Aging Cell)
- "We found a histone deacetylase 6 (HDAC6) inhibitor, CKD-504, changed the tau interactome dramatically to degrade pathological tau not only in AD animal model (ADLP ) brains containing both amyloid plaques and neurofibrillary tangles but also in AD patient-derived brain organoids...We also identified the responsible acetylation sites on tau. These dramatic tau-interactome changes may result in tau degradation, leading to the recovery of synaptic pathology and cognitive decline in the ADLP mice."
Journal • Preclinical
1 to 5
Of
5
Go to page
1